Advertisement

Truvada Approved for HIV Prevention — Physician’s First Watch

Medical News |
July 17, 2012

Truvada Approved for HIV Prevention

The FDA has approved the first drug to reduce the risk for acquiring HIV — so-called preexposure prophylaxis.

Truvada, a combination of the antiretrovirals emtricitabine and tenofovir, is indicated for people at high risk for HIV and is to be used in conjunction with safer sex practices. Before taking Truvada, patients should be tested for HIV to confirm seronegativity.

Clinical trials found that daily Truvada reduced the risk for HIV by 42% in HIV-negative men and transgender women who have sex with men, and by 75% in heterosexual couples in which one partner was HIV positive.

Writing in HIV and ID Observations, Dr. Paul Sax observes: "The challenging issues of defining the best candidates for this strategy — and finding the providers to prescribe it — still remain, but FDA approval should at least help justify insurance coverage if clinicians choose to offer it to their patients."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement